Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppina Andreotti

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Molecular Sciences|August 29, 2019
β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDGMaria Monticelli, Ludovica Liguori, Mariateresa Allocca, et al.
European Journal of Medical Genetics|April 19, 2021
Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19Maria Monticelli, Bruno Hay Mele, Giuseppina Andreotti, et al.
Orphanet Journal of Rare Diseases|December 9, 2010
Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of studyGiuseppina Andreotti, Mario R Guarracino, Marco Cammisa, et al.
Molecules (Basel, Switzerland)|June 27, 2025
<i>In Silico</i> Analysis of Phosphomannomutase-2 Dimer Interface Stability and Heterodimerization with Phosphomannomutase-1Bruno Hay Mele, Jessica Bovenzi, Giuseppina Andreotti, et al.
Genes|March 28, 2024
Drug Repurposing and Lysosomal Storage Disorders: A Trick to TreatBruno Hay Mele, Federica Rossetti, Maria Vittoria Cubellis, et al.
Orphanet Journal of Rare Diseases|August 29, 2023
Congenital disorders of glycosylation: narration of a story through its patentsMaria Monticelli, Tania D'Onofrio, Jaak Jaeken, et al.
Plos One|December 21, 2017
A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDGValentina Citro, Chiara Cimmaruta, Ludovica Liguori, et al.
The Journal of Biological Chemistry|November 17, 2010
Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogueGiuseppina Andreotti, Rosa Maria Vitale, Carmit Avidan-Shpalter, et al.
BMC Bioinformatics|December 1, 2018
Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidaseChiara Cimmaruta, Valentina Citro, Giuseppina Andreotti, et al.
International Journal of Molecular Sciences|June 26, 2025
Bioinformatics-Driven Multi-Factorial Insight into α-Galactosidase MutationsBruno Hay Mele, Federica Rossetti, Giuseppina Andreotti, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Molecular Sciences|August 29, 2019
β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDGMaria Monticelli, Ludovica Liguori, Mariateresa Allocca, et al.
European Journal of Medical Genetics|April 19, 2021
Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19Maria Monticelli, Bruno Hay Mele, Giuseppina Andreotti, et al.
Orphanet Journal of Rare Diseases|December 9, 2010
Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of studyGiuseppina Andreotti, Mario R Guarracino, Marco Cammisa, et al.
Molecules (Basel, Switzerland)|June 27, 2025
<i>In Silico</i> Analysis of Phosphomannomutase-2 Dimer Interface Stability and Heterodimerization with Phosphomannomutase-1Bruno Hay Mele, Jessica Bovenzi, Giuseppina Andreotti, et al.
Genes|March 28, 2024
Drug Repurposing and Lysosomal Storage Disorders: A Trick to TreatBruno Hay Mele, Federica Rossetti, Maria Vittoria Cubellis, et al.
Orphanet Journal of Rare Diseases|August 29, 2023
Congenital disorders of glycosylation: narration of a story through its patentsMaria Monticelli, Tania D'Onofrio, Jaak Jaeken, et al.
Plos One|December 21, 2017
A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDGValentina Citro, Chiara Cimmaruta, Ludovica Liguori, et al.
The Journal of Biological Chemistry|November 17, 2010
Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogueGiuseppina Andreotti, Rosa Maria Vitale, Carmit Avidan-Shpalter, et al.
BMC Bioinformatics|December 1, 2018
Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidaseChiara Cimmaruta, Valentina Citro, Giuseppina Andreotti, et al.
International Journal of Molecular Sciences|June 26, 2025
Bioinformatics-Driven Multi-Factorial Insight into α-Galactosidase MutationsBruno Hay Mele, Federica Rossetti, Giuseppina Andreotti, et al.
Pageof 6